BC-3 (ATCC® CRL-2277)

Organism: Homo sapiens, human  /  Cell Type:: B lymphocyte  /  Tissue: Pleura, pleural effusion  /  Disease: lymphoma

Organism Homo sapiens, human
Tissue Pleura, pleural effusion
Cell Type B lymphocyte
Product Format frozen
Morphology lymphoblast
Culture Properties suspension
Biosafety Level 2  [Cells contain Kaposi's sarcoma-associated herpesvirus genome]

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.

Disease lymphoma
Age 85 years
Gender male
Ethnicity Caucasian
Applications This cell line is a suitable transfection host.
It is ideal for the isolation and study of KSHV.
Disclosure This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC.
Derivation
The cells were established from pleural effusion from a human immunodeficiency virus (HIV) negative patient diagnosed with primary effusion (body cavity based) lymphoma (PEL).
BC-3 is a primary effusion lymphoma cell line originated in 1995 by Leandros Arvanitakis and Ethel Cesarman.
Clinical Data
85 years
Caucasian
male

Antigen Expression
CD30 +; CD38 +; CD45 +; CD 54 +; CD71 +; HLA-DR +; EMA + (epithelial membrane antigen); CD2 -; CD3 -; CD4 -; CD5 -, CD8 -; CD19 -; CD20 -; CD21 -; CD22 -
Comments

The BC-3 cell line contains the viral genome for Kaposi's sarcoma-associated herpesvirus (KSHV, provisionally designated HHV-8).

KSHV is a recently identified and partially uncharacterized virus.

BC-3 cells are negative for both HIV and Epstein-Barr virus (EBV).

They are also reported to be negative for herpes simplex virus 1 & 2 (HSV-1 and HSV-2) and cytomegalovirus (CMV).

The BC-3 cell line allows in vitro culture of KSHV viral genomes in the absence of EBV.

BC-3 has an intact KSHV genome of about 170 kb both in the cell line and in the viral isolate.

The cells do not express B-cell lineage restricted antigens or kappa or lambda immunoglobulin light chains or T-cell lineage-restricted antigens.

The cells do express activation antigens.

Complete Growth Medium RPMI 1640 medium, 80%; fetal bovine serum, 20%
Subculturing

Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 5 x 105 viable cells/mL. Maintain cell density between 5 x 105 and 2 x 106 viable cells/mL.


Medium Renewal: 2 to 3 times a week.  
Cryopreservation
Culture medium, 95%; DMSO, 5%
Culture Conditions
Temperature: 37°C
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
STR Profile
Amelogenin: X
CSF1PO: 11,12
D13S317: 11
D16S539: 12
D5S818: 11,12
D7S820: 10,12
THO1: 6,9
TPOX: 8,11
vWA: 14,18
Name of Depositor Cornell Res. Fndn., Inc.
U.S. Patent Number
Disclosure This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC.
Year of Origin 1995
References

Arvanitakis L, et al. Establishment and characterization of a primary effusion (body cavity- based) lymphoma cell line (BC-3) harboring kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) in the absence of Epstein-Barr virus. Blood 88: 2648-2654, 1996. PubMed: 8839859

Cesarman E, et al. KSHV positive cell lines. US Patent 5,908,773 dated Jun 1 1999

Basic Documentation
References

Arvanitakis L, et al. Establishment and characterization of a primary effusion (body cavity- based) lymphoma cell line (BC-3) harboring kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) in the absence of Epstein-Barr virus. Blood 88: 2648-2654, 1996. PubMed: 8839859

Cesarman E, et al. KSHV positive cell lines. US Patent 5,908,773 dated Jun 1 1999